Announced details
Gastric cancer and gastroesophageal junction cancer, with treatment initially envisaged as third-line therapy. The current combination trial envisages second-line therapy.
5-year overall survival of 13%; the PD-L1 combined positive score increased in 2 cases after OBP-301 administration.
16 patients enrolled in the clinical trial
Presentation concerning an investigator-initiated clinical trial conducted primarily at Cornell University. Capital, personnel and business relationships are Not disclosed.
A university in New York State, USA. The disclosure states that the investigator-initiated clinical trial was conducted primarily at Cornell University. Other details are Not disclosed.
No impact on the Company's results for the fiscal year ending December 2026
The company does not address Contract Value / Offering price.
International Oncolytic Virus Conference（IOVC）2026
| Item | Details |
|---|---|
| Names of Products / Services Covered | Oncolytic virus OBP-301 (Telomelysin), Anti-PD-1 antibody pembrolizumab |
| Counterparty | Cornell University |
| Counterparty overview | A university in New York State, USA. The disclosure states that the investigator-initiated clinical trial was conducted primarily at Cornell University. Other details are Not disclosed. |
| Relationship with the Company | Presentation concerning an investigator-initiated clinical trial conducted primarily at Cornell University. Capital, personnel and business relationships are Not disclosed. |
| Launch date | May 2019 (treatment initiation, actual) |
| Applicable area | Gastric cancer and gastroesophageal junction cancer, with treatment initially envisaged as third-line therapy. The current combination trial envisages second-line therapy. |
| Quantitative Effects | 5-year overall survival of 13%; the PD-L1 combined positive score increased in 2 cases after OBP-301 administration. |
| Usage history | 16 patients enrolled in the clinical trial |
| Impact on Business Performance | No impact on the Company's results for the fiscal year ending December 2026 |
| Source | International Oncolytic Virus Conference（IOVC）2026 |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.A presentation on OBP-301 was given at IOVC2026, held in Iceland.